Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Cancer Drug Resist. 2020 Aug 7;3:572–585. doi: 10.20517/cdr.2020.35

Figure 4.

Figure 4.

No consistent changes were observed in expression of stem cell markers in gemR models compared to drug-sensitive controls. IHC analysis of ALDH1, CD133, and CXCR4 in PA4, PA10, and PA16 control and gemR tumors. Tumor tissue harvested on days 190, 120, and 179 for PA4.gemR, PA10.gemR and PA16.gemR, respectively, was used for IHC analyses. Tumor tissue harvested from gemcitabine-naïve control mice bearing PA4, PA10 or PA16 tumors served as controls. Scale bar = 10 μm. Expression indices of IHC data are shown below each photomicrograph (A); fold changes in protein expression in gemR models compared to their respective parent models. ND = no difference between gemcitabine-naïve control and gemR tumors. Values in the Table were calculated by dividing the EI of each protein determined by IHC expressed by gemR/parent tumor. A change of > 1.5-fold was interpreted as a real increase or decrease (B). gemR: gemcitabine resistance; IHC: immunohistochemistry